CL2022000904A1 - Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). - Google Patents
Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).Info
- Publication number
- CL2022000904A1 CL2022000904A1 CL2022000904A CL2022000904A CL2022000904A1 CL 2022000904 A1 CL2022000904 A1 CL 2022000904A1 CL 2022000904 A CL2022000904 A CL 2022000904A CL 2022000904 A CL2022000904 A CL 2022000904A CL 2022000904 A1 CL2022000904 A1 CL 2022000904A1
- Authority
- CL
- Chile
- Prior art keywords
- formula
- preparation
- vii
- polymorph
- div
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 abstract 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 239000000021 stimulant Substances 0.000 abstract 2
- BWIHJLOBZMKPKS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyrimidine Chemical class N1C=CC(C=2N=CC=CN=2)=N1 BWIHJLOBZMKPKS-UHFFFAOYSA-N 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Procesos nuevos para la preparación de compuestos de Fórmula IV, VII y IA. Algunos de estos compuestos son de utilidad como estimulantes de la guanilato ciclasa soluble (sGC). Otros son intermediarios para usar en la preparación de dichos estimulantes. Estos procesos son adecuados para preparaciones a gran escala y producen 3-(2-pirimidinil)pirazoles de la Fórmula I estables, de gran pureza y rendimientos elevados. La invención ofrece la ventaja adicional de comprender condiciones de reacción sencillas, adecuadas para aumentar la escala en una producción a gran escala. También se proveen nuevos intermediarios para usar en la preparación de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615678P | 2018-01-10 | 2018-01-10 | |
| PCT/CN2018/076982 WO2019161534A1 (en) | 2018-02-22 | 2018-02-22 | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000904A1 true CL2022000904A1 (es) | 2022-10-21 |
Family
ID=65279655
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001814A CL2020001814A1 (es) | 2018-01-10 | 2020-07-07 | Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble. |
| CL2022000904A CL2022000904A1 (es) | 2018-01-10 | 2022-04-08 | Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). |
| CL2022000907A CL2022000907A1 (es) | 2018-01-10 | 2022-04-08 | Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001814A CL2020001814A1 (es) | 2018-01-10 | 2020-07-07 | Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000907A CL2022000907A1 (es) | 2018-01-10 | 2022-04-08 | Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814). |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11274096B2 (es) |
| EP (2) | EP3737679B1 (es) |
| JP (2) | JP7357621B2 (es) |
| KR (1) | KR20200106920A (es) |
| CN (3) | CN118221665A (es) |
| AU (2) | AU2019206560B2 (es) |
| BR (1) | BR112020013985A2 (es) |
| CA (1) | CA3087943A1 (es) |
| CL (3) | CL2020001814A1 (es) |
| ES (1) | ES2963447T3 (es) |
| IL (2) | IL314714A (es) |
| JO (1) | JOP20200165A1 (es) |
| MA (1) | MA51565A (es) |
| MX (3) | MX2020007364A (es) |
| SG (1) | SG11202006311SA (es) |
| TW (2) | TWI821237B (es) |
| WO (1) | WO2019140095A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900096QA (en) | 2016-07-07 | 2019-02-27 | Ironwood Pharmaceuticals Inc | Novel processes for preparation of soluble guanylate cyclase stimulators |
| IL314714A (en) | 2018-01-10 | 2024-10-01 | Cyclerion Therapeutics Inc | PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF SOLUBLE GIONLIGHT CYCLAS FANS |
| CN118221649A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
| CN118221651A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR088020A1 (es) * | 2010-06-30 | 2014-05-07 | Ironwood Pharmaceuticals Inc | Compuestos heterociclicos como estimuladores de sgc |
| KR102362835B1 (ko) * | 2013-03-15 | 2022-02-14 | 사이클리온 테라퓨틱스, 인크. | ｓＧＣ 자극인자 |
| EP3094327A1 (en) * | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| CA2961531A1 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| MX2017003516A (es) * | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc). |
| CN116637076A (zh) * | 2015-11-30 | 2023-08-25 | 赛克里翁治疗有限公司 | 包含sGC刺激剂的固体分散体 |
| SG11201900096QA (en) | 2016-07-07 | 2019-02-27 | Ironwood Pharmaceuticals Inc | Novel processes for preparation of soluble guanylate cyclase stimulators |
| MX2019000138A (es) | 2016-07-07 | 2019-06-10 | Ironwood Pharmaceuticals Inc | Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble. |
| IL314714A (en) | 2018-01-10 | 2024-10-01 | Cyclerion Therapeutics Inc | PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF SOLUBLE GIONLIGHT CYCLAS FANS |
-
2019
- 2019-01-10 IL IL314714A patent/IL314714A/en unknown
- 2019-01-10 CN CN202410363184.1A patent/CN118221665A/zh active Pending
- 2019-01-10 TW TW108101044A patent/TWI821237B/zh active
- 2019-01-10 MA MA051565A patent/MA51565A/fr unknown
- 2019-01-10 EP EP19703440.8A patent/EP3737679B1/en active Active
- 2019-01-10 CN CN201980017700.2A patent/CN111902410B/zh active Active
- 2019-01-10 SG SG11202006311SA patent/SG11202006311SA/en unknown
- 2019-01-10 US US16/961,109 patent/US11274096B2/en active Active
- 2019-01-10 JP JP2020538535A patent/JP7357621B2/ja active Active
- 2019-01-10 BR BR112020013985-8A patent/BR112020013985A2/pt unknown
- 2019-01-10 TW TW112138274A patent/TW202402741A/zh unknown
- 2019-01-10 AU AU2019206560A patent/AU2019206560B2/en active Active
- 2019-01-10 JO JOP/2020/0165A patent/JOP20200165A1/ar unknown
- 2019-01-10 KR KR1020207022640A patent/KR20200106920A/ko active IP Right Grant
- 2019-01-10 WO PCT/US2019/013060 patent/WO2019140095A1/en active Application Filing
- 2019-01-10 CA CA3087943A patent/CA3087943A1/en active Pending
- 2019-01-10 ES ES19703440T patent/ES2963447T3/es active Active
- 2019-01-10 EP EP23187776.2A patent/EP4249469A3/en active Pending
- 2019-01-10 CN CN202410363182.2A patent/CN118184645A/zh active Pending
- 2019-01-10 IL IL275748A patent/IL275748B1/en unknown
- 2019-01-10 MX MX2020007364A patent/MX2020007364A/es unknown
-
2020
- 2020-07-07 CL CL2020001814A patent/CL2020001814A1/es unknown
- 2020-07-13 MX MX2023000044A patent/MX2023000044A/es unknown
- 2020-07-13 MX MX2023000045A patent/MX2023000045A/es unknown
-
2021
- 2021-10-08 US US17/497,352 patent/US11708361B2/en active Active
-
2022
- 2022-04-08 CL CL2022000904A patent/CL2022000904A1/es unknown
- 2022-04-08 CL CL2022000907A patent/CL2022000907A1/es unknown
-
2023
- 2023-04-28 US US18/140,966 patent/US12030874B2/en active Active
- 2023-09-26 JP JP2023162922A patent/JP2023182647A/ja active Pending
- 2023-11-22 AU AU2023270260A patent/AU2023270260A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000904A1 (es) | Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). | |
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
| AR048875A1 (es) | Un proceso para preparar montelukast y compuestos intermedios para el mismo | |
| MX2022001495A (es) | Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble. | |
| MX2018014128A (es) | 6.7.beta-epoxidos esteroideos como intermedios quimicos. | |
| AR118647A1 (es) | Proceso de preparación de 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-deoxi-1-metilamino-d-glucitol | |
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| CL2020003015A1 (es) | Conversión a escala preparativa de goniautoxinas en neosaxitoxina | |
| JOP20180126A1 (ar) | عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان | |
| CU20220013A7 (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
| AR086987A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| WO2020127208A8 (en) | Pharmaceutical process and intermediates | |
| CU20200047A7 (es) | Compuestos de alquinileno sustituidos como agentes anticancerígenos | |
| AR098053A1 (es) | Proceso para la síntesis industrial de lurasidona | |
| MX2021007511A (es) | Procedimiento para la preparacion de anilinas sustituidas. | |
| CO2022001513A2 (es) | Proceso e intermediarios para la preparación de piroxasulfona | |
| CO2021015370A2 (es) | Proceso de preparación de compuestos de estrobilurina activos como fungicidas e intermedios de los mismos | |
| MX2023000059A (es) | Metodo de preparacion de compuesto de fenilisoxazolina. | |
| EA202091664A1 (ru) | Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы | |
| JP2016108332A (ja) | アミノ化合物の製造方法 | |
| PE20230183A1 (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina | |
| MX2024001312A (es) | Procedimiento para la preparacion de derivados de (2,2,2-trifluoroetil)sulfanilanilina. | |
| UA123716U (uk) | Обетіхолева кислота | |
| AR120241A1 (es) | Procedimiento para la preparación del ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico |